Latest News

NewsChannel 5, the CBS-affiliate in Nashville, TN, USA has featured the Bladder Cancer Survivor's Story of Mary Beth Ballard Murray, who is coming up on her 5 years survivorship.

An article by Ashish Kamat, highlighting Blue Light Cystoscopy with Cysview and current evidence on recurrence and progression.

Oslo, Norway, 29 November 2018: Photocure ASA (OSE: PHO) is pleased to announce that Photocure will be presenting at the Nordic-American Life Science Conference in New York today. The presentation will be held by Daniel Schneider, President and CEO of Photocure ASA.

Oslo, Norway, 8 November 2018: Photocure ASA (OSE:PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2018, contributing to total Hexvix/Cysview revenues of NOK 43.5 million (Q3 2017: NOK 35.5 million) and a recurring EBITDA of NOK -3.1 million (NOK -9.6 million).

Photocure will present its third quarter report on Thursday 8 November 2018 at Hotel Continental, Oslo, Norway. The presentation will begin at 08:30 (CET).

New data on Urine Cytology in the management of bladder cancer patients is now published in the prestigious peer reviewed BJUI journal (British Journal of Urology International). The analysis shows that relying on Cytology alone, especially for high risk patients, would miss early detection and BCG unresponsiveness in NMIBC (non-muscle invasive bladder cancer).

The BLADDR 2018 Congress took place in Madrid September 20-21. It is the 3rd Global Congress on Bladder Cancer and a major educational multidisciplinary event purely focusing on bladder cancer attended by specialists from all over the world.

Oslo, Norway, 20 September 2018: Photocure ASA (OSE: PHO), announces today that Daniel Schneider has been appointed President and Chief Executive Officer of Photocure. Mr Schneider joins Photocure from the position of General Manager for Ablynx N.V. in North America.

Blue light cystoscopy with Cysview was featured in Renal&Urology News by Dr.Gupta and Dr. Bivalacqua from the James Buchanan Brady Urologic Institute, Johns Hopkins Hospital in Baltimore. The authors highlight the essence of performing accurate cystoscopy and transurethral resection of bladder tumor (TURBT) for proper diagnosis, staging and surveillance of tumors in bladder cancer patients. Use of enhanced cystoscopy shows increased detection both in the operating room at the time of TURBT and in the outpatient surveillance setting.

Read more: https://bit.ly/2Om6uaB 

Oslo, Norway, August 27, 2018: Photocure ASA, The Bladder Cancer Company, announces today that an exclusive distribution agreement for the Nordic area for an innovative and patented medical device has been signed with Combat Medical (www.combat-medical.com). The device is designed for the delivery of Hyperthermic Intra-Vesical Chemotherapy (HIVEC^®) for non-muscle invasive bladder cancer and has a strong strategic and synergistic fit with current business.

Blue Light Cystoscopy with Cysview for surveillance cystoscopy featured in Health News Digest today:

Blue-light Technology improves identification of Bladder Cancer. Read the story and watch the video from UT Southwestern Medical Center in Dallas, TX, U.S.A here.